<DOC>
	<DOCNO>NCT01262885</DOCNO>
	<brief_summary>GSK2251052 ( ( S ) -3- ( aminomethyl ) -7- ( 3-hydroxypropoxy ) -1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride ) Gram negative antibacterial compound currently development treatment hospital acquire Gram negative infection ( include E. coli , K. pneumoniae , Enterobacter spp . ) This study conduct two ( 2 ) part , single oral dos explore Part A ( 500 , 1000 , 2000 mg ) repeat oral dos ( 1000 2000 mg , b.i.d . ) explore Part B . Parts A B single-blind , randomize , placebo-controlled , dose-rising study healthy subject evaluate safety , tolerability pharmacokinetics oral GSK2251052 .</brief_summary>
	<brief_title>A Randomized , Single Blind , Placebo Controlled Study Evaluate Safety , Tolerability , Pharmacokinetics Single Oral Doses Repeat Escalating Oral Doses GSK2251052 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Abnormal LFT test may repeat discretion Investigator . If abnormality repeat , subject would eligible inclusion . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects coagulation , reticulocyte , Hgb value outside normal range always exclude enrollment . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Male subject female partner childbearing potential must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication least 90 day postlast dose . Body weight &gt; 50 kg BMI within range 19 32 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTc , QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Subjects asthma history asthma , ( e.g. , FTIH risk bronchoconstriction unknown , compound specific risk bronchoconstriction ) . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . A history orthostatic hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
	<keyword>single dose</keyword>
	<keyword>antibiotic</keyword>
	<keyword>repeat dose</keyword>
	<keyword>GSK2251052</keyword>
	<keyword>safety</keyword>
</DOC>